A composition useful for promoting a desired oral microbiota to treat an allergy related respiratory condition in a subject in need of such treatment, the composition including an amino acid containing ingredient including individual molecules of L-arginine; the composition in a configuration to be maintained within the oral cavity for a period of at least about 30 seconds to about an hour, the desired oral microbiota including Veillonella and Streptococcus.

A composition useful for promoting a desired oral microbiota to treat an allergy related respiratory condition in a subject in need of such treatment, the composition including an amino acid containing ingredient including individual molecules of L-arginine; the composition in a configuration to be maintained within the oral cavity for a period of at least about 30 seconds to about an hour, the desired oral microbiota including Veillonella and Streptococcus.

The present invention provides compositions and formulations capable of maintaining or promoting the growth of certain strains of Lactobacilli spp. The compositions and formulations generally comprise only a single therapeutic agent selected from the group consisting of isomaltulose, maltitol, pullulan, maltotriose, 2-deoxy-D-ribose, 1-kestose and erlose. The single therapeutic agent is the sole source of carbon for bacterium when administered to a user. Despite comprising only a single therapeutic agent the compositions have been shown to promote the growth and maintenance of beneficial Lactobacilli and to effectively inhibit the growth of pathogens associated with urogenital infections. As such administration of the compositions maintain a healthy microflora balance in the urogenital area.

The present invention provides compositions and formulations capable of maintaining or promoting the growth of certain strains of Lactobacilli spp. The compositions and formulations generally comprise only a single therapeutic agent selected from the group consisting of isomaltulose, maltitol, pullulan, maltotriose, 2-deoxy-D-ribose, 1-kestose and erlose. The single therapeutic agent is the sole source of carbon for bacterium when administered to a user. Despite comprising only a single therapeutic agent the compositions have been shown to promote the growth and maintenance of beneficial Lactobacilli and to effectively inhibit the growth of pathogens associated with urogenital infections. As such administration of the compositions maintain a healthy microflora balance in the urogenital area.

The present invention provides compositions and formulations capable of maintaining or promoting the growth of certain strains of Lactobacilli spp. The compositions and formulations generally comprise only a single therapeutic agent selected from the group consisting of isomaltulose, maltitol, pullulan, maltotriose, 2-deoxy-D-ribose, 1-kestose and erlose. The single therapeutic agent is the sole source of carbon for bacterium when administered to a user. Despite comprising only a single therapeutic agent the compositions have been shown to promote the growth and maintenance of beneficial Lactobacilli and to effectively inhibit the growth of pathogens associated with urogenital infections. As such administration of the compositions maintain a healthy microflora balance in the urogenital area.

The invention discloses preparations comprising L-rhamnose, and the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in the form of either free fatty acids, fatty acid salts having an organic counter ion selected from lysine, arginine, ornithine, choline and mixtures of the same, or mixtures of free fatty acids and omega-3 fatty acid salts having an organic counter ion selected from lysine, arginine, ornithine, choline and use of a preparation as a feed or food supplement or in pharmaceutical compositions.

The invention discloses preparations comprising L-rhamnose, and the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in the form of either free fatty acids, fatty acid salts having an organic counter ion selected from lysine, arginine, ornithine, choline and mixtures of the same, or mixtures of free fatty acids and omega-3 fatty acid salts having an organic counter ion selected from lysine, arginine, ornithine, choline and use of a preparation as a feed or food supplement or in pharmaceutical compositions.

Disclosed are an enzyme-treated royal jelly composition comprising carrageenan and enzyme-treated royal jelly treated with a peptidase; an enzyme-treated royal jelly composition comprising at least one member selected from the group consisting of galactomannan, galactomannan-containing polysaccharides, and xanthan gum, at least one member selected from the group consisting of carrageenan, dextrin, and pullulan, and enzyme-treated royal jelly treated with a peptidase; and an enzyme-treated royal jelly composition comprising dextrin, at least one member selected from the group consisting of carrageenan and pullulan, and enzyme-treated royal jelly treated with a peptidase.

Disclosed are an enzyme-treated royal jelly composition comprising carrageenan and enzyme-treated royal jelly treated with a peptidase; an enzyme-treated royal jelly composition comprising at least one member selected from the group consisting of galactomannan, galactomannan-containing polysaccharides, and xanthan gum, at least one member selected from the group consisting of carrageenan, dextrin, and pullulan, and enzyme-treated royal jelly treated with a peptidase; and an enzyme-treated royal jelly composition comprising dextrin, at least one member selected from the group consisting of carrageenan and pullulan, and enzyme-treated royal jelly treated with a peptidase.

A method of promoting a desired oral microbiota to treat an inflammation condition related to an allergic reaction in a subject in need of such treatment including providing a preformulated edible composition including an amino acid containing ingredient comprising L-arginine, the composition configured to be present as individual molecules of L-arginine within an oral cavity of the subject; removing a biofilm from surfaces within an oral cavity including exposing the biofilm to a biofilm degrading enzyme; wherein during or following removal of the biofilm, the composition is provided contained and at least partially dissolved within an oral cavity of the subject for a period of at least from about 30 seconds to about an hour on a daily basis comprising at least one day to promote an increased concentration of selected oral microbiota, the selected microbiota including Veillonella and Streptococcus.